AMG 595, an Anti-EGFRvIII Antibody–Drug Conjugate, Induces Potent Antitumor Activity against EGFRvIII-Expressing Glioblastoma
Kevin J. Hamblett(Seagen (United States)), William C. Fanslow(Laboratoire d'Innovation Thérapeutique), Taruna Arora(Amgen (United States)), David Meininger(Amgen (United States)), Ian N. Foltz(Amgen (Canada)), Carl J. Kozlosky(Amgen (United States)), Sophia Siu(Amgen (United States)), Wesley Chang(California Institute of Technology), Brian Twomey(Amgen (United States)), Hua Liu(China Pharmaceutical University), Qing Chen(Integrated Chinese Medicine (China)), Steven Vonderfecht(Amgen (United States)), John S. Hill(University of Alabama), Esther S. Trueblood(Amgen (United States))
Cited by 99
Related Papers
An Essential Role for Ectodomain Shedding in Mammalian Development
|Science|1998|1.6k
Effects of Drug Loading on the Antitumor Activity of a Monoclonal Antibody Drug Conjugate
|Clinical Cancer Research|2004|1.2k
Molecular Cloning of the Interleukin-1β Converting Enzyme
|Science|1992|1.1k
Oxygen Reduction Electrocatalyst Based on Strongly Coupled Cobalt Oxide Nanocrystals and Carbon Nanotubes
|Journal of the American Chemical Society|2012|791